
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Nov 10, 2025 13:44 pm UTC| Business Health Science
Cogent Biosciences (NASDAQ: COGT) shares skyrocketed over 120% after the biotech company announced groundbreaking results from its Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib for patients with...

Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Nov 09, 2025 00:37 am UTC| Business Health
Pfizer has sealed a $10 billion acquisition of obesity drug developer Metsera, marking a major victory in the rapidly expanding weight-loss drug market. The New York-based pharmaceutical giant outbid Danish rival Novo...

Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Nov 08, 2025 01:48 am UTC| Business Health
Pfizer Inc. has reportedly increased its takeover offer for Metsera, a U.S.-based obesity drug developer, signaling its determination to outpace Danish rival Novo Nordisk in the lucrative weight-loss treatment market....

Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Nov 07, 2025 09:54 am UTC| Business Health
Shares in Novo Nordisk dropped nearly 3% on Friday after the Danish pharmaceutical giant and U.S. competitor Eli Lilly agreed to cut prices for their leading GLP-1 weight-loss drugs under a new deal with the U.S....

U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Nov 07, 2025 01:49 am UTC| Health Politics
A panel of independent U.S. vaccine experts has announced plans to review the long-standing recommendation for administering the hepatitis B vaccine at birth. The Vaccine Integrity Project, an organization focused on...

Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Nov 04, 2025 02:15 am UTC| Business Health Law
Pfizer has filed a second lawsuit against Danish pharmaceutical giant Novo Nordisk, accusing the company of deliberately stalling its $9 billion bid for biotech firm Metsera to hinder competition in the booming obesity...

Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Nov 01, 2025 10:43 am UTC| Politics Governance Health Economy
Americans preparing to enroll in 2026 Affordable Care Act (ACA) health insurance plans are facing steep premium hikes, with monthly costs expected to more than double on average. The sharp rise stems from the expiration of...